Sirion To Submit NDA For Ocular Antiviral Gel Virgan In Fourth Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm licenses the compound from France-based Laboratoires Théa, marketer of the herpes simplex keratitis treatment in Europe.
You may also be interested in...
Sirion’s Durezol Gets Priority Review, Late June Action Date
CEO Butler tells “The Pink Sheet” DAILY Durezol would improve on the current standard of care by offering twice-daily dosing for post-operative ocular inflammation.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.